7 completed, 4 terminated. 9 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Terminated 1 |
Follow dexelvucitabine: new trials by email Literature Review of dexelvucitabine trials Research Report on dexelvucitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment Elvucitabine - HIV Infections | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 7 | 2008-05-01 | 2023-08-14 |
| Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Elvucitabine, Lamivudine, Emtricitabine - Human Immunodeficiency Virus (HIV)-1 Infection | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 4 | 2006-09-01 | 2023-08-14 |
| Safety Study of Elvucitabine in HIV-1 Subjects elvucitabine - HIV Infections | Phase 2 | Completed | Thomas Jefferson University | 5 | 2006-09-01 | 2009-02-04 |
| Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants Elvucitabine, Lamivudine, Tenofovir - HIV Infections | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 76 | 2006-05-01 | 2023-08-30 |
| Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs Dexelvucitabine - HIV Infections, Human Immunodeficiency Virus | Phase 2 | Terminated | Incyte Corporation | 250 | 2006-04-01 | 2018-08-23 |
| Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Elvucitabine, Lamivudine - HIV Infections | Phase 1 / Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 20 | 2006-03-31 | 2023-08-25 |
| Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B ACH126, 433 - Chronic Hepatitis B | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 85 | 2002-07-01 | 2021-02-18 |
| Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection ACH-126,443, Lamivudine, Placebo - Hepatitis B, Chronic | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 79 | 2002-02-01 | 2021-02-18 |
| A Study of DPC 817 in HIV-Infected Males DPC 817 - HIV Infections | Phase 1 | Completed | Pharmasset | 30 | 2005-07-19 | |
| Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. ACH126-443 (Beta-L-Fd4C) - HIV Infections | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 60 | 2015-12-30 | |
| Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection. ACH-126, 443 (beta-L-Fd4C) - Chronic Hepatitis B | Not applicable | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2009-08-19 |
HIV Infections (7) · Hepatitis B, Chronic (3) · Acquired Immunodeficiency Syndrome (2)
Alexion Pharmaceuticals, Inc. (8) · Incyte Corporation (1) · Pharmasset (1) · Thomas Jefferson University (1)
United States (9) · Germany (2) · Puerto Rico (2) · Bulgaria (1) · Canada (1) · China (1) · Dominican Republic (1) · Federal Republic of Yugoslavia (1) · Spain (1)